BAM
APLS

Blueshift Asset Management’s Apellis Pharmaceuticals APLS Stock Holding History

Blueshift Asset Management’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-4,027
Closed -$255K – 992
2021
Q2 		$255K Buy
+4,027
New +$208K 0.01% 774

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Blueshift Asset Management's APLS Position: Q3 2021 in Review

Blueshift Asset Management sold out of Apellis Pharmaceuticals (APLS) in Q3 2021, closing a stake of 4,027 shares — an estimated $255K sold.

Blueshift Asset Management first reported a position in APLS in Q2 2021 and held it in 1 quarter. The position peaked at $255K in Q2 2021. 180 funds tracked by Wall St. Rank hold APLS as of Q3 2021.

  • Blueshift Asset Management reported no remaining Apellis Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Blueshift Asset Management sold 4,027 Apellis Pharmaceuticals shares in Q3 2021, an estimated $255K.
  • Blueshift Asset Management first reported a position in Apellis Pharmaceuticals in Q2 2021 and held it in 1 quarter.
  • Blueshift Asset Management's Apellis Pharmaceuticals position peaked at $255K in Q2 2021.
  • 180 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q3 2021.

Based on Blueshift Asset Management's 13F filing for Q3 2021, filed 12 Nov 2021.